Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.

Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, Düring M, Matthews DR; LEAD-2 Study Group.

Diabetes Care. 2009 Jan;32(1):84-90. doi: 10.2337/dc08-1355. Epub 2008 Oct 17.

2.

Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study.

Nauck M, Frid A, Hermansen K, Thomsen AB, During M, Shah N, Tankova T, Mitha I, Matthews DR.

Diabetes Obes Metab. 2013 Mar;15(3):204-12. doi: 10.1111/dom.12012. Epub 2012 Oct 11. Review.

PMID:
22985213
3.

Liraglutide: a review of its use in type 2 diabetes mellitus.

Croom KF, McCormack PL.

Drugs. 2009 Oct 1;69(14):1985-2004. doi: 10.2165/11201060-000000000-00000. Review.

PMID:
19747013
4.

Liraglutide: from clinical trials to clinical practice.

Gough SC.

Diabetes Obes Metab. 2012 Apr;14 Suppl 2:33-40. doi: 10.1111/j.1463-1326.2012.01576.x. Review.

PMID:
22405267
5.

The efficacy and safety of liraglutide.

Jeong KH, Yoo BK.

Int J Clin Pharm. 2011 Oct;33(5):740-9. doi: 10.1007/s11096-011-9552-8. Epub 2011 Sep 28. Review.

PMID:
21952951
6.

The design of the liraglutide clinical trial programme.

Nauck MA.

Diabetes Obes Metab. 2012 Apr;14 Suppl 2:4-12. doi: 10.1111/j.1463-1326.2012.01573.x. Review.

PMID:
22405264
7.

Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus.

Neumiller JJ, Campbell RK.

Ann Pharmacother. 2009 Sep;43(9):1433-44. doi: 10.1345/aph.1M134. Epub 2009 Jul 28. Review.

PMID:
19638470
8.

[Liraglutide: a human GLP-1 analogue for the treatment of diabetes mellitus type 2].

Jahn E, Sausele T.

Med Monatsschr Pharm. 2009 Nov;32(11):402-7. Review. German.

PMID:
19947303
9.

Review of the therapeutic uses of liraglutide.

Ryan GJ, Foster KT, Jobe LJ.

Clin Ther. 2011 Jul;33(7):793-811. doi: 10.1016/j.clinthera.2011.06.004. Epub 2011 Jul 8. Review.

PMID:
21741090
10.

Liraglutide for the treatment of type 2 diabetes: a clinical update.

Peters KR.

Am J Ther. 2013 Mar-Apr;20(2):178-88. doi: 10.1097/MJT.0b013e3182204c16. Review.

PMID:
21734532
11.

[Liraglutide: new results in the treatment of type 2 diabetes mellitus].

Mateos JL, Wajchenberg BL.

Drugs Today (Barc). 2012 Jul;48 Suppl B:1-17. doi: 10.1358/dot.2012.48(Suppl.B).1876681. Review. Portuguese.

PMID:
23082308
12.

Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus.

Iltz JL, Baker DE, Setter SM, Keith Campbell R.

Clin Ther. 2006 May;28(5):652-65. Review.

PMID:
16861088
13.

Is liraglutide a useful addition to diabetes therapy?

Mikhail NE.

Endocr Pract. 2010 Nov-Dec;16(6):1028-37. doi: 10.4158/EP10076.RA. Review.

PMID:
20439238
14.

Liraglutide for the treatment of type 2 diabetes.

Shyangdan D, Cummins E, Royle P, Waugh N.

Health Technol Assess. 2011 May;15 Suppl 1:77-86. doi: 10.3310/hta15suppl1/09. Review.

15.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
16.
17.

Clinical pearls for initiating and utilizing liraglutide in patients with type 2 diabetes.

Gross B.

J Pharm Pract. 2013 Apr;26(2):144-50. doi: 10.1177/0897190012465985. Epub 2012 Dec 2. Review.

PMID:
23204146
18.

Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes.

Thompson AM, Trujillo JM.

Ann Pharmacother. 2015 Mar;49(3):351-9. doi: 10.1177/1060028014564180. Epub 2015 Jan 6. Review.

PMID:
25565404
19.

Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes.

Trujillo JM, Nuffer W.

Ann Pharmacother. 2014 Nov;48(11):1494-501. doi: 10.1177/1060028014545807. Epub 2014 Aug 18. Review.

PMID:
25136065
20.

Insulin degludec/liraglutide: innovation-driven combination for advancement in diabetes therapy.

Kumar A.

Expert Opin Biol Ther. 2014 Jun;14(6):869-78. doi: 10.1517/14712598.2014.904851. Epub 2014 Apr 5. Review.

PMID:
24702171
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk